50 related articles for article (PubMed ID: 38752436)
1. Liposome Nanomedicine Based on Tumor Cell Lysate Mitigates the Progression of Lynch Syndrome-Associated Colon Cancer.
Wang P; Zhong W; Huang Q; Zhu Y; Chen L; Ye K
ACS Biomater Sci Eng; 2024 May; 10(5):3136-3147. PubMed ID: 38663028
[TBL] [Abstract][Full Text] [Related]
2. Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation.
Xu X; Xie T; Zhou M; Sun Y; Wang F; Tian Y; Chen Z; Xie Y; Wu R; Cen X; Zhou J; Hou T; Zhang L; Huang C; Zhao Q; Wang D; Xia H
Nat Commun; 2024 May; 15(1):4237. PubMed ID: 38762492
[TBL] [Abstract][Full Text] [Related]
3. Sonogenetics-controlled synthetic designer cells for cancer therapy in tumor mouse models.
Gao T; Niu L; Wu X; Dai D; Zhou Y; Liu M; Wu K; Yu Y; Guan N; Ye H
Cell Rep Med; 2024 May; 5(5):101513. PubMed ID: 38608697
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitors stabilize the expression of PD-L1 on cell membrane depending on the phosphorylation of GSK3β.
Gao L; Liu Y; Liu J; Li J; Li H; Liu Y; Meng F; Du X; Gao Y; Li J; Qin FX
Cancer Med; 2024 May; 13(10):e7083. PubMed ID: 38752436
[TBL] [Abstract][Full Text] [Related]
5. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.
Van Der Kraak L; Goel G; Ramanan K; Kaltenmeier C; Zhang L; Normolle DP; Freeman GJ; Tang D; Nason KS; Davison JM; Luketich JD; Dhupar R; Lotze MT
J Immunother Cancer; 2016; 4():65. PubMed ID: 27777774
[TBL] [Abstract][Full Text] [Related]
6. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
7. SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1.
Zhang N; Dou Y; Liu L; Zhang X; Liu X; Zeng Q; Liu Y; Yin M; Liu X; Deng H; Song D
EBioMedicine; 2019 Feb; 40():151-162. PubMed ID: 30711516
[TBL] [Abstract][Full Text] [Related]
8. (-)-4-
Song G; Lu Y; Tang L; Li M; Yin J; Chen H; Ling J
Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):806-812. PubMed ID: 34694960
[TBL] [Abstract][Full Text] [Related]
9. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.
Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM
Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247
[TBL] [Abstract][Full Text] [Related]
10. Proton Pump Inhibitors and Cancer: Current State of Play.
Bridoux M; Simon N; Turpin A
Front Pharmacol; 2022; 13():798272. PubMed ID: 35359844
[No Abstract] [Full Text] [Related]
11. Gastrointestinal: Pembrolizumab-induced gastric ulcer occurring as an immune-related adverse event.
Terasaki K; Ueno A; Mizuno C; Shima T; Okanoue T
J Gastroenterol Hepatol; 2022 Aug; 37(8):1472. PubMed ID: 35141946
[No Abstract] [Full Text] [Related]
12. Harnessing big data to characterize immune-related adverse events.
Jing Y; Yang J; Johnson DB; Moslehi JJ; Han L
Nat Rev Clin Oncol; 2022 Apr; 19(4):269-280. PubMed ID: 35039679
[TBL] [Abstract][Full Text] [Related]
13. pH Low Insertion Peptide-Modified Programmed Cell Death-Ligand 1 Potently Suppresses T-Cell Activation Under Acidic Condition.
Sun Y; Hu L; Yang P; Zhang M; Wang X; Xiao H; Qiao C; Wang J; Luo L; Feng J; Zheng Y; Wang Y; Shi Y; Chen G
Front Immunol; 2021; 12():794226. PubMed ID: 35003115
[TBL] [Abstract][Full Text] [Related]
14. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors.
Giordan Q; Salleron J; Vallance C; Moriana C; Clement-Duchene C
Front Immunol; 2021; 12():716317. PubMed ID: 34777340
[TBL] [Abstract][Full Text] [Related]
15. Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer.
Qin BD; Jiao XD; Zhou XC; Shi B; Wang J; Liu K; Wu Y; Ling Y; Zang YS
Oncoimmunology; 2021; 10(1):1929727. PubMed ID: 34350061
[TBL] [Abstract][Full Text] [Related]
16. WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression.
Wu M; Xia X; Hu J; Fowlkes NW; Li S
Nat Commun; 2021 Jun; 12(1):3500. PubMed ID: 34108491
[TBL] [Abstract][Full Text] [Related]
17. Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma.
Cybulska-Stopa B; Ziętek M; Czarnecka AM; Piejko K; Dziura R; Galus Ł; Ziółkowska B; Kieszko S; Kempa-Kamińska N; Calik J; Seredyńska J; Gądek K; Zemełka T; Teterycz P; Kubiatowski T; Suwiński R; Mackiewicz J; Rutkowski P
J Dermatolog Treat; 2022 Jun; 33(4):2168-2174. PubMed ID: 34057374
[TBL] [Abstract][Full Text] [Related]
18. Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma.
Jun T; Ozbek U; Dharmapuri S; Hardy-Abeloos C; Zhu H; Lin JY; Personeni N; Pressiani T; Nishida N; Lee PC; Lee CJ; Hildebrand H; Nimkar N; Paul S; Fessas P; Naeem M; Bettinger D; Khan U; Saeed A; Huang YH; Kudo M; Rimassa L; Marron TU; Pinato DJ; Ang C
Ther Adv Med Oncol; 2021; 13():17588359211010937. PubMed ID: 33995594
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
